Sign in
Back
Dramatic reduction in tumor burden with neoadjuvant sunitinib prior to bilateral nephron-sparing surgery
Journal article   Peer reviewed

Dramatic reduction in tumor burden with neoadjuvant sunitinib prior to bilateral nephron-sparing surgery

Michael A Gorin, Obi Ekwenna, Mark S Soloway and Gaetano Ciancio
Urology (Ridgewood, N.J.), Vol.79(2), pp.e11-e11
2012-02
DOI: https://doi.org/10.1016/j.urology.2011.04.018
PMID: 21676439

Abstract

Neoplasms, Multiple Primary - surgery Carcinoma, Renal Cell - diagnostic imaging Humans Middle Aged Carcinoma, Renal Cell - surgery Male Tomography, X-Ray Computed Antineoplastic Agents - therapeutic use Neoplasms, Multiple Primary - diagnostic imaging Tumor Burden Nephrectomy - methods Kidney Neoplasms - surgery Organ Sparing Treatments - methods Kidney Neoplasms - diagnostic imaging Indoles - therapeutic use Neoadjuvant Therapy Carcinoma, Renal Cell - drug therapy Kidney Neoplasms - drug therapy Pyrroles - therapeutic use Neoplasms, Multiple Primary - drug therapy
Neoadjuvant sunitinib has recently been described for the management of renal cell carcinoma. We present the pre and posttreatment images of a 49-year-old male with bilateral biopsy-proven clear cell renal cell carcinoma who underwent treatment with sunitinib prior to nephron-sparing surgery. After four four-week cycles of daily 50 mg sunitinib, the patient demonstrated a dramatic reduction in tumor burden allowing for successful bilateral partial nephrectomy.

Metrics

9 Record Views
8 Times Cited - Web of Science

InCites Highlights

These are selected metrics from InCites Benchmarking & Analytics tool, related to this output

Citation topics
1 Clinical & Life Sciences
1.233 Pelvic & Renal Disorders
1.233.501 Renal Cell Carcinoma
Web Of Science research areas
Urology & Nephrology
ESI research areas
Clinical Medicine

UN Sustainable Development Goals (SDGs)

This output has contributed to the advancement of the following goals:

#3 Good Health and Well-Being

Source: InCites

Details